Health Care · Pharmaceutical Preparations

AMRX Amneal Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 172312898 filings
Russell 2000

AMRX at a glance

Amneal Pharmaceuticals, Inc. (AMRX, SEC CIK 1723128) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as September 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.0 billion (up 8.0% from FY2024) and net income of $72.1 million. Diluted EPS was $0.22.
  • As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Amneal Pharmaceuticals, Inc. (AMRX) shares worth $1.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Kiely John on August 13, 2026 of 50,000 shares at $17.64 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$3.0B
+8.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
33 funds
$1.8B · −1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 7.01 · Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development and commercialization of complex generic and branded pharmaceutical products focusing on high-barrier, high-value formulations
  • New product emphasis: Launch of five oncology biosimilars including Boncresa™ and Oziltus™ FDA-approved in Dec 2025, plus first complex inhalation aerosol generics from Ireland facility
  • Strategic shift: Expanded respiratory platform with injectable drug/device combos and long-acting injectables targeting hospital sector growth
  • Quantitative highlight: Pipeline includes 61 pending ANDAs, 43 in development with 95% non-oral solids, FDA approval of multiple key respiratory and biosimilar products in 2025
  • Noteworthy fact: First commercial approvals for products produced at new Ireland manufacturing facility in 2025, signifying geographic and complexity expansion

Risk Factors

  • Tax Receivable Agreement (TRA) liability contingent $129.1M as of Dec 31, 2025 from basis adjustments under IRC Section 754
  • Geopolitical exposure not specified; no direct mention of macroeconomic or international risk in text
  • Litigation and government investigations with uncertain outcomes; accruals based on low end of probable loss range
  • Potential volatility in tax valuation allowance reversals impacting contingent TRA liabilities and related income statement charges

Management Discussion & Analysis

  • Net cash from operating activities $340.0M in 2025 vs $295.1M in 2024; 15.2% increase but lower YoY excluding $52.4M prior litigation settlement
  • Net cash used in investing activities $112.3M in 2025 vs $63.0M in 2024; 78.2% increase due to higher capex and property deposits
  • Net cash used in financing activities $31.5M in 2025 vs $211.8M in 2024; 85.1% decrease due to debt refinancing and related party note repayment
  • Goodwill allocated: Specialty $366.3M, Affordable Medicines $159.7M, AvKARE $69.5M; no goodwill impairment in 2025
  • Management identified critical accounting estimates in sales deductions, business combinations, goodwill impairment, income taxes, and contingencies

AI summary of the AMRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $862.7M, up 10.0% YoY from $784.5M
  • Gross margin 38.7% vs 34.9%; operating income $95.4M vs $70.3M
  • Specialty strongest: revenue $150.3M, up 20.0%; gross margin 69.2% vs 41.1%
  • AvKARE weakest: revenue $165.3M, down 16.7%; operating income $17.4M, down 35.7%
  • Operating cash flow $50.3M year-to-date vs $209.7M; Kashiv acquisition funding drove $476.7M net borrowings
  • Tariff uncertainty and potential future generic-drug tariffs could increase costs and pressure margins; 2026 capital expenditures estimated at $150.0M

Risk Factors

  • New acquisition risk: Kashiv integration and biosimilar execution following $421.0 million cash consideration and 28.9 million shares issued
  • Regulatory risk: proposed generic-drug tariffs could reach 100% after July 31, 2028 and 200% thereafter
  • Legal risk: $8.0 million government-investigation charge recognized during the quarter
  • Operational risk: severe rain temporarily suspended an India facility and caused $5.4 million property and inventory charges
  • Financial risk: Kashiv financing increased revolver borrowings to $180.0 million and added $350.0 million Term Loan Due 2032 borrowings

AI summary of the AMRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Amneal scheduled a November 3, 2026 conference call and webcast to discuss results
  • Investor presentation and webcast available through Amneal’s Investor Relations website

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced November 3, 2026
  • Investors should review Exhibit 99.1 for financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $863M, up 10%, led by Affordable Medicines growth of 19% and Specialty growth of 20%
  • Adjusted EBITDA $207M, up 30%, while GAAP net loss reached $22M due to acquisition costs and higher taxes
Filed Oct 23, 2026Full analysis →

Item EX-99.2: Item EX-99.2

  • Kashiv acquisition closed August 10, 2026, adding a wholly owned biopharmaceutical research, development and manufacturing business to Amneal
  • Consideration included $375 million cash, 28,942,108 Amneal shares and up to $350 million contingent regulatory milestones plus potential royalties

Item EX-99.1: Item EX-99.1

  • Going-concern warning: $106.3M operating cash burn and $27.7M accumulated deficit create material funding risk through 2026
  • $149.3M long-term debt added in 2025, increasing leverage despite $23.5M cash and restricted cash

Item EX-99.3: Item EX-99.3

  • Kashiv acquisition completed August 10, 2026 for preliminary aggregate consideration of $1.31B, including $491.6M equity and $266.1M closing cash
  • Amneal issued 28.9M Class A shares, creating dilution of approximately 9% versus pro forma basic shares of 342.3M
Filed Aug 10, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Amneal completed the Acquisition, marking a transition from announced transaction to closed deal
  • Exhibit 99.1 press release contains transaction details and expected strategic implications

Item EX-99.1: Item EX-99.1

  • Completed Kashiv acquisition, creating an integrated biosimilars platform spanning R&D, manufacturing, and commercialization
  • Biosimilars become a major long-term growth pillar, extending Amneal’s growth profile into the 2030s

Item 2.01: Completion of Acquisition or Disposition of Assets

  • Item 2.01 indicates a completed acquisition or disposition, with transaction details contained in the filing’s Introductory Note
  • Investors should review the Introductory Note for assets involved, consideration paid or received, and expected strategic impact

Item 2.03: Creation of a Direct Financial Obligation

  • Direct financial obligation details are contained in the filing’s Introductory Note and Item 1.01
  • Investors should review the related agreement for borrowing amount, pricing, maturity and repayment obligations

Item 1.01: Entry into a Material Definitive Agreement

  • $350 million incremental term loan from Bank of America funded acquisition consideration
  • Debt increase raises leverage and future interest obligations, with repayment terms governed by the amended credit agreement

Item 3.02: Unregistered Sales of Equity Securities

  • Amneal issued 28,942,098 Class A shares to acquisition sellers as stock consideration
  • Transaction used Securities Act Section 4(a)(2) private-placement exemption, avoiding immediate public registration

AI summaries of AMRX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AMRX

Don't miss the next AMRX filing

  • Alerts as it files. A push when AMRX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AMRX, by share count.
  • Ask anything. An AI agent that reads every AMRX filing and answers with sources.

AMRX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
BUCHI J KEVINGSep 17, 2026-
BUCHI J KEVINMSep 11, 2026-
BUCHI J KEVINMSep 11, 2026$14.45
BOYER ANDREW SGSep 1, 2026-
BOYER ANDREW SGAug 21, 2026-
Kiely JohnGAug 13, 2026-
Kiely JohnSellAug 13, 2026$17.64
Daly Jason B.SellAug 12, 2026$17.40

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.4B$2.8B$3.0B
Gross Profit-$1.0B$1.1B
Operating Income-$249.3M$394.1M
Net Income--$116.9M$72.1M
Gross Margin-36.5%36.9%
Op. Margin-8.9%13.1%
Net Margin--4.2%2.4%
Balance Sheet
Total Assets-$3.5B$3.7B
Equity$19.8M-$109.3M-$70.8M
ROE-107.0%-101.8%
Per Share
EPS-$-0.38$0.22
Cash Flow
Operating CF-$295.1M$340.0M
CapEx-$51.9M$70.1M

Source: XBRL data in Amneal Pharmaceuticals, Inc. (AMRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AMRX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AMRX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202633$1.84B
Q2 202634$1.45B
Q1 202634$1.00B
Q4 202530$899.3M
Q3 202530$698.1M
Q2 202529$539.3M
Q1 202527$409.5M
Q4 202421$342.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 238 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AMRX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 3, 2026Analysis-
8-KOct 23, 2026Analysis-
4Sep 21, 2026--
4Sep 14, 2026--
4Sep 2, 2026--
4Aug 25, 2026--
4Aug 14, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
8-KAug 10, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 3, 2026Analysis-
8-KJul 31, 2026Analysis-
8-KJul 30, 2026Analysis-
4May 12, 2026-
4May 8, 2026-
4May 8, 2026-
4May 8, 2026-
4May 8, 2026-

Related Health Care companies

All Health Care →

AMRX SEC filings: frequently asked questions

Which institutions hold AMRX stock?

As of September 30, 2026, the largest Amneal Pharmaceuticals, Inc. (AMRX) holders among the 13F filers tracked by SignalX were BlackRock ($541.3 million), Vanguard Portfolio Management LLC ($249.0 million), Vanguard Capital Management LLC ($160.9 million), State Street Corp ($150.5 million), Citadel Advisors LLC ($140.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AMRX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.0 billion (up 8.0% from FY2024) and net income of $72.1 million. Diluted EPS was $0.22. The figures come from the XBRL data in the 10-K.

What are the main risks in AMRX's latest 10-K?

In the 10-K filed February 27, 2026, Amneal Pharmaceuticals, Inc. (AMRX) flagged: Tax Receivable Agreement (TRA) liability contingent $129.1M as of Dec 31, 2025 from basis adjustments under IRC Section 754. Geopolitical exposure not specified; no direct mention of macroeconomic or international risk in text. (AI summary of the Risk Factors section.)

What did AMRX report in its latest 8-K?

Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K on November 3, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Amneal scheduled a November 3, 2026 conference call and webcast to discuss results.

What are the latest AMRX SEC filings?

Amneal Pharmaceuticals, Inc. (AMRX) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on September 21, 2026.

What is AMRX's SEC CIK number?

Amneal Pharmaceuticals, Inc. (AMRX)'s SEC Central Index Key (CIK) is 1723128. EDGAR lists every AMRX filing under that number.

Ask anything about AMRX

The research agent reads AMRX's filings, financials, insider trades and 13F holders, then answers with sources.